神经内分泌肿瘤患者中[18F]AlF-NOTA-奥曲肽PET/MRI与[68Ga]Ga-DOTATATE PET/CT的前瞻性比较
一项前瞻性多中心试验的第二臂纳入10例组织学确诊的神经内分泌肿瘤患者,在静脉注射4 MBq/kg [18F]AlF-OC后2小时行全身PET/MRI,并与3个月内完成的[68Ga]Ga-DOTATATE PET/CT比较。共检出195个病灶,[18F]AlF-OC检出193个、[68Ga]Ga-DOTATATE检出167个;[18F]AlF-OC检出率99.1%对91.4%,非劣效检验p=0.0001,193个[18F]AlF-OC病灶中96.2%经MRI确认为NET病灶,33个增量病灶中91%经MRI确认。
要点
- [18F]AlF-OC检出率99.1%对[68Ga]Ga-DOTATATE 91.4%,非劣效检验p=0.0001。
- 193个[18F]AlF-OC病灶中96.2%经同步MRI确认为NET病灶。
- 33个增量病灶中91%经MRI确认,考虑为真阳性。
核心结论
- [18F]AlF-OC的检出率在数值上高于[68Ga]Ga-DOTATATE且非劣效于后者。
- [18F]AlF-OC病灶、尤其是增量病灶,经MRI确认在超过90%的病灶中为真阳性。
- 作者认为这些数据进一步验证[18F]AlF-OC可作为临床实践中SSTR PET的新选择。
研究设计与样本
- 前瞻性多中心试验第二臂,纳入10例组织学确诊的神经内分泌肿瘤患者。
- 患者均在3个月内完成标准诊疗的[68Ga]Ga-DOTATATE PET/CT。
- 静脉注射4 MBq/kg [18F]AlF-OC后2小时行全身PET/MRI(TOF,3 T,GE Signa)。
- 对PET阳性病灶评估MRI上对应病灶,计算每份扫描的检出率(DR)和每例患者的差异检出率(DDR)。
- 试验注册号ClinicalTrials.gov NCT04552847,注册日期2020年9月17日。
主要发现
- 共检出195个独立病灶,[68Ga]Ga-DOTATATE检出167个,[18F]AlF-OC检出193个。
- [18F]AlF-OC的检出率为99.1%,[68Ga]Ga-DOTATATE为91.4%,非劣效检验p=0.0001。
- 193个[18F]AlF-OC病灶中96.2%经MRI确认为NET病灶。
- [18F]AlF-OC识别33个增量病灶,其中91%经MRI确认并考虑为真阳性。
关键数值与推荐
- [18F]AlF-OC检出率99.1%对[68Ga]Ga-DOTATATE 91.4%,非劣效检验p=0.0001。
- 193个[18F]AlF-OC病灶中96.2%经MRI确认为NET病灶。
- 33个增量病灶中91%经MRI确认并考虑为真阳性。
临床怎么用
- 作者认为[18F]AlF-OC可作为临床实践中SSTR PET的新选择。
局限性
- 上一项报告因伦理和实际原因缺乏组织学确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18F]AlF-OC PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18F]AlF-OC ("incremental lesions"). METHODS: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient. RESULTS: In total, 195 unique lesions were detected: 167 with [68Ga]Ga-DOTATATE and 193 with [18F]AlF-OC. The DR for [18F]AlF-OC was 99.1% versus 91.4% for [68Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18F]AlF-OC, of which 91% were confirmed by MRI and considered true positives. CONCLUSION: The DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta. CLINICALTRIALS: gov/study/NCT04552847.
引用
- Boeckxstaens L, Pauwels E, Vandecaveye V, et al. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res. 2023. PMID: 37261615. doi:10.1186/s13550-023-01003-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。